MelvinAlbertChurchillJr.MDFACR

Rheumatology • Lincoln, NE

Osteoporosis & Bone Metabolism

Founder Arthritis Center of Nebraska ;Director Physician Research Collaboration

Join to view full profile

Dr. Churchill is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Churchill's full profile

Already have an account?

Office
3901 Pine Lake Rd
Suite 120
Lincoln, NE 68516
Phone+1 402-420-1212

Fax+1 402-328-0961

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Rheumatology, 1977 - 1978
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1973 - 1977
University of Nebraska Medical Center College of MedicineInternship, Internal Medicine, 1972 - 1973
University of Nebraska College of MedicineClass of 1972

Certifications & Licensure

NE State Medical License 1972 - 2026
IA State Medical License 1975 - 1979
MN State Medical License 1973 - 1979
WI State Medical License 1977 - 1978
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013
Fellow (FACR) American College of Rheumatology

Clinical Trials

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
Completed
Phase 2
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Start of enrollment: 2014 Jan 01
Terminated
Phase 3
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 May 02
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Start of enrollment: 2016 Aug 02
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) Start of enrollment: 2020 Jul 01
Active, not recruiting
Phase 3
Roles: Contact
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) Start of enrollment: 2020 Jul 01
Recruiting
Phase 3
Roles: Contact
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis Start of enrollment: 2022 Jun 30
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study.
Alan Kivitz, Liliana Sedova, Melvin Churchill, Roshan Kotha, Atul Singhal
Arthritis & Rheumatology. 2024-09-19
9 citations
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.
Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F Merola
The Journal of Rheumatology. 2022-08-01
11 citations
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAI...
Tuhina Neogi, David J Hunter, Melvin Churchill, Ivan Shirinsky, Alexander White
Arthritis Research & Therapy. 2022-03-29

Professional Memberships

American Medical Association - AMA
Member
American College of Rheumatology - ACR
Fellow
International Society of Clinical Densitometry
Member